Publications by authors named "Dimitri Breems"

Claim this Profile
D
Different features of acute myeloid leukemia stem cell quantification in intensively treated patients.
Lok Lam Ngai, Tom Reuvekamp, Diana Hanekamp, Fleur Janssen, Laura Oudshoorn-van Marsbergen, Dimitri A Breems

Haematologica· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial.
Tim R Mocking, Lukas H Haaksma, Tom Reuvekamp, Angèle Kelder, Willemijn J Scholten, Dimitri A Breems

Leukemia· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A revised prognostic model for patients with acute myeloid leukemia and first relapse.
Niek G van der Maas, Dimitri Breems, Clara P W Klerk, Thomas Pabst, Patrycja Gradowska

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients.
Sjoerd J F Hermans, Jurjen Versluis, Erik D van Werkhoven, Yvette van Norden, Jeroen J W M Janssen, Dimitri A Breems

Br J Haematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents.
Tom Reuvekamp, Lok Lam Ngai, Daphne den Hartog, Jannemieke Carbaat-Ham, Mona M H E Fayed, Dimitri Breems

Leukemia· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.
Gerwin Huls, Dana A Chitu, Lidwine Tick, Rinske Boersma, Dimitri Breems

Ann Hematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world insights on the management of immune-mediated thrombotic thrombocytopenic purpura with caplacizumab.
Daan Dierickx, Thierry Connerotte, Julie Dallemagne, Ann De Becker, Ine Moors, Dimitri Breems

Blood Vessel Thromb Hemost· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial.
Niek G van der Maas, Jurjen Versluis, Kazem Nasserinejad, Joost van Rosmalen, Thomas Pabst, Dimitri Breems

Blood Cancer J· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.
Jesse M Tettero, Lok Lam Ngai, Costa Bachas, Dimitri A Breems, Thomas Fischer

Haematologica· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
Jacobien R Hilberink, Isabelle A van Zeventer, Dana A Chitu, Thomas Pabst, Saskia K Klein, Dimitri Breems

Blood Cancer J· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Perception Is Correlated with Health-Related Quality of Life in Patients Suffering from Myelodysplastic Syndromes: Results of the Belgian Be-QUALMS Study.
Bert Heyrman, Stef Meers, Ann De Becker, Kristien Wouters, Achiel Van Hoof, Dimitri Breems

Cancers (Basel)· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial.
Lok Lam Ngai, Diana Hanekamp, Fleur Janssen, Jannemieke Carbaat-Ham, Maaike A M A Hofland, Dimitri A Breems

Blood· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis.
Jesse M Tettero, Waleed K W Al-Badri, Lok Lam Ngai, Costa Bachas, Dimitri A Breems

Front Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
Mikkael A Sekeres, Michael Schuster, Magalie Joris, Jürgen Krauter, Johan Maertens, Dimitri Breems

Ann Hematol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.
Tim Grob, Adil S A Al Hinai, Mathijs A Sanders, François G Kavelaars, Melissa Rijken, Dimitri A Breems

Blood· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab.
Nathalie Van der Moeren, Philippe Selhorst, My Ha, Laura Heireman, Pieter-Jan Van Gaal, Dimitri Breems

Viruses· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial.
Anita W Rijneveld, Bronno van der Holt, Okke de Weerdt, Bart J Biemond, Arjen A van de Loosdrecht, Dimitri A Breems

Blood Adv· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed.
Katerina Bakunina, Hein Putter, Jurjen Versluis, Eva A S Koster, Bronno van der Holt, Dimitri A Breems

Cancer Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature.
Anke Delie, Anke Verlinden, Karolien Beel, Dries Deeren, Dominiek Mazure, Dimitri Breems

Acta Clin Belg· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes.
Guillermo Garcia-Manero, Maria Diez-Campelo, Edo Vellenga, Meagan A Jacoby, Brayan Merchan, Dimitri Breems

Am J Hematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS.
Jeroen Janssen, Bob Löwenberg, Markus Manz, Mario Bargetzi, Bart Biemond, Dimitri Breems

Cancers (Basel)· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.
Bob Löwenberg, Thomas Pabst, Johan Maertens, Patrycja Gradowska, Bart J Biemond, Dimitri A Breems

Blood Adv· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.
Gerwin Huls, Dana A Chitu, Thomas Pabst, Saskia K Klein, Georg Stussi, Dimitri Breems

Blood Adv· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation.
Burak Kalin, Yvette van Norden, Michel van Gelder, Dimitri Breems, Johan Maertens

Blood Adv· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical implications of measurable residual disease in AML: Review of current evidence.
Ine Moors, Karl Vandepoele, Jan Philippé, Dries Deeren, Dominik Selleslag, Dimitri Breems

Crit Rev Oncol Hematol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis